CTN-194 (PICCO): Design of a trial of citalopram for the prevention of depression and its consequences in HIV-Hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy

Contemporary Clinical Trials

Volumn 29, Issue 4, 2008, Pages 617-630

  Klein, Marina B ^a   Cooper, Curtis ^b   Brouillette, Marie Josée ^a   Sheehan, Nancy L ^c,d   Benkelfat, Chawki ^a   Annable, Lawrence ^a   Weston, Francine ^a   Kraus, Deborah ^e   Singer, Joel ^e  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e Canadian HIV Trials Network   (Canada)

Author keywords

Citalopram; Depression; Hepatitis C virus; HIV; Pegylated interferon alpha; Randomized controlled trial; Ribavirin; Telepsychiatry

Indexed keywords

CITALOPRAM; PEGETRON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2B; PLACEBO; REBETRON; RIBAVIRIN;

ANXIETY; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL RESEARCH; DEPRESSION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOTHERAPY; METHODOLOGY; MIXED INFECTION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SELECTION; PLANNING; PROPHYLAXIS; QUALITY OF LIFE; RANDOMIZATION; TELEPSYCHIATRY;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIVIRAL AGENTS; CANADA; CITALOPRAM; DEPRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2B; PSYCHOMETRICS; RIBAVIRIN; SAMPLE SIZE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 44149102182     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2008.01.001     Document Type: Article

References (70)

1. World Health Organization. HIV/HCV Co-infection, 2006. (http://www.euro.who.int/HEN/Syntheses/hepatitisC/20050411_7).
2. Mai A.L., Yim C., O'Rourke K., et al. The interaction of human immunodeficiency virus infection and hepatitis B virus infection in infected homosexual men. J Clin Gastroenterol 22 (1996) 299-304
3. Martin P., Di Bisceglie A.M., Kassianides C., et al. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. Gastroenterology 97 (1989) 1559-1561
4. Sanchez-Quijano A., Andreu J., Gavilan F., et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 14 (1995) 949-953
5. Soto B., Sanchez-Quijano A., Rodrigo L., et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 26 (1997) 1-5
6. Graham C.S., Baden L.R., Yu E., et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 33 (2001) 562-569
7. Darby S.C., Ewart D.W., Giangrande P.L., et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 350 (1997) 1425-1431
8. Staples Jr. C.T., Rimland D., and Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis 29 (1999) 150-154
9. Bica I., McGovern B., Dhar R., et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 32 (2001) 492-497
10. Macias J., Melguizo I., Fernandez-Rivera F.J., et al. Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy. Eur J Clin Microbiol Infect Dis 21 (2002) 775-781
11. Salmon-Ceron D., Lewden C., Morlat P., et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 42 (2005) 799-805
12. Selik R.M., Byers Jr. R.H., and Dworkin M.S. Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr 29 (2002) 378-387
13. Tatsunami S., Taki M., Shirahata A., et al. Increasing incidence of critical liver disease among causes of death in Japanese hemophiliacs with HIV-1. Acta Haematol 111 (2004) 181-184
14. Strader D.B., Wright T., Thomas D.L., et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 39 (2004) 1147-1171
15. Sherman M., Shafran S., Burak K., et al. Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol 21 Suppl C (2007) 25C-34C
16. Carrat F., Bani-Sadr F., Pol S., et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. Jama 292 (2004) 2839-2848
17. Chung R.T., Andersen J., Volberding P., et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 351 (2004) 451-459
18. Laguno M., Murillas J., Blanco J.L., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. Aids 18 (2004) F27-F36
19. Torriani F.J., Rodriguez-Torres M., Rockstroh J.K., et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 351 (2004) 438-450
20. Fleming C.A., Craven D.E., Thornton D., et al. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 36 (2003) 97-100
21. Fultz S, Butt A, Weissman S, et al. Evaluation and treatment of HIV+veterans coinfected with hepatitis C. Presented at XIV International AIDS Conference, Barcelona, July 7-12 2002.
22. Taylor L, Tashima K, Alt E, et al. Addiction and mental illness are barriers to hepatitis C treatment among HIV/hepatitis C virus coinfected individuals. Presented at 14th International AIDS Conference, Barcelona, Spain, July 7-12 2002.
23. Loftis J.M., and Hauser P. The phenomenology and treatment of interferon-induced depression. J Affect Disord 82 (2004) 175-190
24. Schaefer M., Engelbrecht M.A., Gut O., et al. Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry 26 (2002) 731-746
25. Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology 36 (2002) S237-S244
26. Schering Canada Inc. Rebetron Product Monograph. 2002.
27. Ciesla J.A., and Roberts J.E. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry 158 (2001) 725-730
28. Starace F., Ammassari A., Trotta M.P., et al. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 31 Suppl 3 (2002) S136-S139
29. Morikawa O., Sakai N., Obara H., et al. Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 349 (1998) 317-324
30. Wichers M., and Maes M. Mechanisms of interferon-alpha-induced depressive symptoms. Acta Neuropsychiatrica 14 (2002) 103-105
31. Musselman D.L., Lawson D.H., Gumnick J.F., et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 344 (2001) 961-966
32. Capuron L., Gumnick J.F., Musselman D.L., et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 26 (2002) 643-652
33. Schaefer M., Schwaiger M., Garkisch A.S., et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 42 (2005) 793-798
34. Loftis J.M., and Hauser P. Safety of the treatment of interferon-alpha-induced depression. Psychosomatics 44 (2003) 524-526
35. U.S. Department of Health and Human Services Health Resources and Services Administration HIV/AIDS Bureau. Expanding Access to Treatment for HIV/HCV Coinfected Patients, 2006. (http://hab.hrsa.gov/publications/August2006/).
36. Soriano V., Nunez M., Camino N., et al. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. Antivir Ther 9 (2004) 505-509
37. Laguno M., Larrousse M., Murillas J., et al. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin. J Acquir Immune Defic Syndr 44 (2007) 174-178
38. Ballesteros A.L., Fuster D., Planas R., et al. Role of viral kinetics under HCV therapy in HIV/HCV-coinfected patients. J Antimicrob Chemother 55 (2005) 824-827
39. Schaefer M., Schmidt F., Folwaczny C., et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 37 (2003) 443-451
40. McHutchison J.G., Manns M., Patel K., et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123 (2002) 1061-1069
41. Sola R., Galeras J.A., Montoliu S., et al. Poor response to hepatitis C virus (HCV) therapy in HIV-and HCV-coinfected patients is not due to lower adherence to treatment. AIDS Research and Human Retroviruses 22 (2006) 393-400
42. Liu H., Golin C.E., Miller L.G., et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 134 (2001) 968-977
43. Turner B.J. Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. J Infect Dis 185 Suppl 2 (2002) S143-S151
44. Beck A., Steer R., and Brown G. BDI-II manual (1996), Psychological Corporation, New York
45. Demyttenaere K., and De Fruyt J. Getting what you ask for: on the selectivity of depression rating scales. Psychother Psychosom 72 (2003) 61-70
46. Castellon S.A., Hinkin C.H., Wood S., et al. Apathy, depression, and cognitive performance in HIV-1 infection. J Neuropsychiatry Clin Neurosci 10 (1998) 320-329
47. Ferrando S.J., Rabkin J.G., de Moore G.M., et al. Antidepressant treatment of depression in HIV-seropositive women. J Clin Psychiatry 60 (1999) 741-746
48. Lyketsos C.G., Hutton H., Fishman M., et al. Psychiatric morbidity on entry to an HIV primary care clinic. Aids 10 (1996) 1033-1039
49. Zisook S., Peterkin J., Goggin K.J., et al. Treatment of major depression in HIV-seropositive men. HIV Neurobehavioral Research Center Group. J Clin Psychiatry 59 (1998) 217-224
50. Dieperink E., Ho S.B., Thuras P., et al. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 44 (2003) 104-112
51. Dwight M.M., Kowdley K.V., Russo J.E., et al. Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res 49 (2000) 311-317
52. Hauser P., Khosla J., Aurora H., et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 7 (2002) 942-947
53. DSM-IV® Sourcebook. American Psychiatric Association, 1994.
54. First M., Spitzer R., Gibbon M., et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition (SCID-I/NP) (2002), Biometrics Research, New York State Psychiatric Institute, New York
55. Klein M, Rouleau D, Pourreaux K, et al. HIV-hepatitis C (HCV) co-infected individuals face numerous obstacles to health. Presented at 13th Annual Canadian Conference on HIV/AIDS Research, Montreal, QC, May 13-16 2004.
56. Christie T., Tyndall M., Braitstein P., et al. An ethical analysis of providing effective hepatitis C treatment to HIV co-infected patients and other vulnerable populations. Canadian Journal of Infectious Diseases 15 (2004) Abstract 408
57. Shafran S., Mashinter L., Lindemulder A., et al. Eligibility of HIV-HCV co-infected adults for HCV treatment. Canadian Journal of Infectious Diseases 15 (2004) Abstact 268P
58. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 32 (1959) 50-55
59. Bonaccorso S., Marino V., Biondi M., et al. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 72 (2002) 237-241
60. American Psychiatric Association. Resource Document On Telepsychiatry Via Videoconferencing (Arlington, VA), 2007. (http://www.psych.org/psych_pract/tp_paper.cfm#def).
61. De Las Cuevas C., Arredondo M.T., Cabrera M.F., et al. Randomized clinical trial of telepsychiatry through videoconference versus face-to-face conventional psychiatric treatment. Telemed J E Health 12 (2006) 341-350
62. Ruskin P.E., Silver-Aylaian M., Kling M.A., et al. Treatment outcomes in depression: comparison of remote treatment through telepsychiatry to in-person treatment. Am J Psychiatry 161 (2004) 1471-1476
63. Hyler S.E., Gangure D.P., and Batchelder S.T. Can telepsychiatry replace in-person psychiatric assessments? A review and meta-analysis of comparison studies. CNS Spectr 10 (2005) 403-413
64. Knobel H., Alonso J., Casado J.L., et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA study. Aids 16 (2002) 605-613
65. Carretero M.D., Burgess A.P., Soler P., et al. Reliability and validity of an HIV-specific health-related quality-of-life measure for use with injecting drug users. Aids 10 (1996) 1699-1705
66. Schering Canada Inc. Pegetron Product Monograph (2005)
67. Gheorghe L., Iacob S., Sporea I., et al. Efficacy, tolerability and predictive factors for early and sustained virologic response in patients treated with weight-based dosing regimen of PegIFN alpha-2b ribavirin in real-life healthcare setting. J Gastrointestin Liver Dis 16 (2007) 23-29
68. Jacobson IM, Brown RS, Freilich B, et al. Weight-based ribavirin dosing (WBD) increases sustained viral response (SVR) in patients with chronic hepatitis C (CHC): final results of the WIN-R study, a US community based trial. Presented at 56th Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, November 11-15 2005.
69. Beauchamp L., Murphy T., and Klein M.B. Prevalence of depression among HIV infected and HIV/HCV co-infected patients. Canadian Journal of Infectious Diseases 15 (2004) Abstract 445P
70. Pharmascience. pms-Citalopram Product Monograph. 2005.